Location out of bounds


Resources for journalists

All Press Releases
Versiti Logo

BloodCenter of Wisconsin presents at Thrombosis & Hemostasis Societies of North America 2018 Summit

Milwaukee – February 26, 2018

Milwaukee – Feb. 26, 2018 – BloodCenter of Wisconsin, part of Versiti, will offer 10 unique presentations, posters and short group discussions at the Thrombosis & Hemostasis Societies of North America 2018 Summit March 8-10 in San Diego.

A schedule of BloodCenter’s events is posted here. Be sure to visit BloodCenter at Booth 8, outside of the main entrance to the exhibit hall.

BloodCenter of Wisconsin’s Diagnostic Laboratories has more than 70 years of unparalleled experience in benign hematology. Its multidisciplinary diagnostic approach and patient-specific precision medicine practices ensure accurate test results and the highest level of patient care.

Diagnostic Laboratories areas of expertise in benign hematology include:

Hematology Genetics: BloodCenter is a leading laboratory partner and recognized leader across the continuum of care of patients with hematologic disorders. It provides premier service through the integration of functional diagnostics and disease-focused genetic sequencing, clearly reported to guide superior patient care. 

Each of its genetics panels is specifically designed for hematology diagnosis, with careful gene-by-gene selection for clinical validity and utility. These custom-built panels are designed to include every clinically relevant part of each gene expertly selected for inclusion. Supplemental Sanger sequencing to optimize reliable and accurate detection of variants is included in its panel design. This approach to panel design maximizes diagnostic utility and minimizes the risk of off-target results or incidental findings more likely to be identified by broader testing platforms.

BloodCenter ensures the most precise analysis through its multidisciplinary team of physicians and scientific directors who provide clinical consulting and interpretation of test results.

von Willebrand Disease Testing

BloodCenter of Wisconsin continues to expand the frontier of von Willebrand Disease diagnostics through advanced and comprehensive laboratory medicine. In 2017, BloodCenter launched VWF GPIbM Activity, a Ristocetin-independent activity assay, an alternative to VWF Ristocetin Cofactor Activity with superior precision and sensitivity. While the VWF: RCO assay has been used for decades to measure VWF platelet binding activity, the assay’s imprecision and poor sensitivity are significant drawbacks*. Furthermore, the new GPIbM is not subject to falsely low values seen in individuals who possess the common p.D1472H polymorphism or the rare p.P1467S variant, both of which confound the accurate diagnosis of VWD*.

*citations available

About BloodCenter of Wisconsin

BloodCenter of Wisconsin, part of Versiti, is a not-for-profit organization headquartered in Milwaukee, Wis., that specializes in blood services, esoteric diagnostic testing, organ, tissue and stem cell donation, medical services and leading-edge research. We advance patient care by delivering life-saving solutions grounded in unparalleled medical and scientific expertise. The collective efforts of Versiti affiliates result in improved patient outcomes, expanded access to care, and cost efficiencies for healthcare systems nationwide. For more information, visit www.bcw.edu and www.versiti.org.


Contact Us

Fay Spano

Director, Public Relations and Corporate Communications
Email (414) 937-6124

Other Press Releases

Giving Warms the Heart, #Pledge3Donations This Year

Community leaders join Versiti Blood Center of Wisconsin for National Blood Donor Month telethon

January 2, 2020

In honor of January National Blood Donor Month, community leaders will join Versiti Blood Center of Wisconsin on Tuesday, Jan. 7 for a telethon to encourage blood donation.

Read More
Versiti Blood Center of Ohio

Gratitude extended to blood donors as the 2019 Blood Battle comes to end

December 2, 2019

The final score: University of Michigan – 1,938 donations, The Ohio State University –1,525 donations.

Read More
3d illustration of an activated platelets

Versiti Launches New Test to Improve HIT Diagnostics, Reduce Progression to Deadly Conditions Caused

December 2, 2019

Versiti, Inc., a national leader in blood health innovation, is excited to announce the launch of its new P-Selectin Expression Assay (PEA).

Read More

This website uses cookies to ensure you get the best experience on our website. Learn more